La Jolla Pharmaceutical Company – Consensus Indicates Potential 138.7% Upside

Broker Ratings

La Jolla Pharmaceutical Company found using ticker (LJPC) have now 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 20 and 4 and has a mean target at 10.67. Given that the stocks previous close was at 4.47 this would indicate that there is a potential upside of 138.7%. The 50 day moving average now sits at 4.48 and the 200 day MA is 4.33. The company has a market cap of $120m. You can visit the company’s website by visiting:

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index